| Perdonà et al. [15] Di Lorenzo et al. [16] |
Validated questionnaire (EORTC QLQ-c30) |
Arm A: prophylactic RT. Arm B: tamoxifen. Arm C: control |
No differences in mean global health scores were found when comparing the two intervention groups. |
QoL was not negatively affected by either treatment option. |
| Boccardo et al. [7] |
Self-adminstered, validated questionnaire. |
Arm A: tamoxifen or anastrozole. Arm B: control |
No differences between groups concerning sexual interest. Minor difference related to sexual functioning, scores increased at 6-months for the anastrozole and control groups while the tamoxifen group remained unchanged. Data on other domains were not reported in detail. |
No harmful effects on QoL were caused by the addition of tamoxifen or anastrozole to bicalutamide. Tamoxifen did not worsen sexual interest or functioning. |
| Fradet et al [10] |
Patients were interviewed |
Arm A: tamoxifen daily (1–20 mg). Arm B: placebo |
Arm A: erectile dysfunction was lowest in the 20 mg group (2.9%) and highest in the 10 mg group (11.8%). Arm B: erectile dysfunction in 3.3%. |
No major differences in erectile dysfunction between placebo and the different tamoxifen doses. |
| Saltzstein et al. [4] |
Self-adminstered questionnaire |
Arm A: tamoxifen or anastrozole daily.Arm B: placebo |
Fewer than 5% in all treatment groups reported loss of libido or erectile difficulties. |
No evidence of increased sexual dysfunction with either treatment. |
